Veroux Massimiliano, Scollo Paolo, Giambra Martina Maria, Roscitano Giuseppe, Giaquinta Alessia, Setacci Francesco, Veroux Pierfrancesco
Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.
Maternal and Child Department, Obstetrics and Gynecology, Cannizzaro Hospital, 95123 Catania, Italy.
J Clin Med. 2024 Jan 29;13(3):775. doi: 10.3390/jcm13030775.
Uterus transplantation (UTx) is currently the only available treatment for absolute uterine factor infertility. More than 90 uterus transplantations have been performed worldwide, mostly from living donors. Living-donor (LD) UTx is a challenging surgical procedure since it poses ethical issues, and it is a high-risk and invasive surgery with higher hysterectomy-related risks compared to conventional hysterectomy. A total of 59 living-donor hysterectomies have been reported in the literature, including 35 performed with a laparotomic approach, 20 with a robotic approach and 4 with a laparoscopic approach. The mean donor age was 45.6 ± 9.1 years, and 22 were unrelated with the recipients, 34 were emotionally related (27 mothers, 5 sisters, 2 mother's sisters). The mean recipient age was 28.8 ± 4.5 years. Mayer-Rokitansky-Küster-Hauser syndrome was the most common indication for uterus transplant. Robotic living-donor hysterectomy had the longest operative time but resulted in a lower blood loss and postoperative stay compared to laparotomic and laparoscopic approaches. Twenty-nine births from LD-UTx have been reported, four after robotic living-donor hysterectomy and twenty-five after a laparotomic procedure. UTx is now an effective treatment for women with UFI. While living-donor UTx in some cases may be considered an experimental procedure, it offers the extraordinary possibility to give women the opportunity to have a pregnancy. Many efforts should be made to reduce the potential risks for donors, including the use of mini-invasive techniques, and the efficacy of UTx in the recipients, giving the potential harm of immunosuppression in a recipient of a non-life-saving organ.
子宫移植(UTx)是目前治疗绝对子宫因素不孕症的唯一可用方法。全球已进行了90多例子宫移植,大多数来自活体供体。活体供体(LD)子宫移植是一项具有挑战性的外科手术,因为它存在伦理问题,并且与传统子宫切除术相比,它是一种高风险的侵入性手术,子宫切除相关风险更高。文献中总共报道了59例活体供体子宫切除术,其中35例采用开腹手术,20例采用机器人手术,4例采用腹腔镜手术。供体的平均年龄为45.6±9.1岁,其中22例与受体无血缘关系,34例有情感关联(27例为母亲,5例为姐妹,2例为姨妈)。受体的平均年龄为28.8±4.5岁。迈耶-罗基坦斯基-库斯特-豪泽综合征是子宫移植最常见的适应症。与开腹手术和腹腔镜手术相比,机器人活体供体子宫切除术的手术时间最长,但失血量和术后住院时间较低。据报道,LD-UTx术后有29例分娩,其中4例在机器人活体供体子宫切除术后,25例在开腹手术后。UTx现在是治疗子宫因素不孕症女性的有效方法。虽然在某些情况下,活体供体UTx可能被视为一种实验性手术,但它为女性提供了怀孕的非凡可能性。应做出许多努力来降低供体的潜在风险,包括使用微创技术,以及UTx在受体中的疗效,同时考虑到非救命器官受体中免疫抑制的潜在危害。